A Phase 3 interventional study of Sitagliptin phosphate and Pioglitazone hydrochloride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 74 in phase 3, and was the 49th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,615 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 5th largest by enrollment of the 170 interventional ones that give a count, is one of 26 that started in 2008, is one of 86 in phase 3, and was the 55th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sitagliptin phosphate · Drug: Matching placebo to pioglitazone · Drug: Metformin
Drug: Pioglitazone hydrochloride · Drug: Matching placebo to sitagliptin · Drug: Metformin
Drug: Pioglitazone hydrochloride · Drug: Matching placebo to sitagliptin · Drug: Metformin
Drug: Pioglitazone hydrochloride · Drug: Matching placebo to sitagliptin · Drug: Metformin
Drug: Sitagliptin phosphate · Drug: Pioglitazone hydrochloride · Drug: Metformin
Drug: Sitagliptin phosphate · Drug: Pioglitazone hydrochloride · Drug: Metformin
Drug: Sitagliptin phosphate · Drug: Pioglitazone hydrochloride · Drug: Metformin
Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
Also known as: Januvia, Tesavel, Xelevia, Ristaben
Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
Also known as: Actos
Matching placebo to sitagliptin orally once daily for 54 weeks.
Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
Change From Baseline in Hemoglobin A1C (A1C) at Week 24
A1C represents the percentage of glycosylated hemoglobin.
Time frame: Baseline and Week 24
Change From Baseline in A1C at Week 54
A1C represents the percentage of glycosylated hemoglobin.
Time frame: Baseline and Week 54
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
Time frame: Baseline and Week 24
Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24
PMG was measured using the Meal Tolerance Test (MTT).
Time frame: Baseline and Week 24
Change From Baseline in FPG at Week 54
Time frame: Baseline and Week 54
Change From Baseline in 2-Hour PMG at Week 54
PMG was measured using the Meal Tolerance Test (MTT).
Time frame: Baseline and Week 54
| Milestone | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg |
|---|---|---|---|---|---|---|---|
| Started | 231 | 230 | 233 | 230 | 230 | 231 | 230 |
| Completed | 175 | 158 | 168 | 167 | 182 | 178 | 179 |
| Not completed | 56 | 72 | 65 | 63 | 48 | 53 | 51 |
| Withdrew: Adverse event | 6 | 13 | 9 | 10 | 6 | 8 | 4 |
| Withdrew: Contraindication | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Creatinine / creatinine clearance | 2 | 1 | 2 | 3 | 2 | 1 | 1 |
| Withdrew: Excluded medication | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Hyperglycemia | 2 | 6 | 4 | 2 | 5 | 1 | 1 |
| Withdrew: Hypoglycemia | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 6 | 6 | 6 | 2 | 3 | 0 |
| Withdrew: Lost to follow-up | 11 | 14 | 21 | 13 | 8 | 16 | 13 |
| Withdrew: Physician decision | 5 | 2 | 2 | 5 | 2 | 3 | 4 |
| Withdrew: Pregnancy | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 6 | 1 | 0 | 1 | 4 | 2 | 1 |
| Withdrew: Withdrawal by subject | 18 | 27 | 19 | 23 | 19 | 18 | 26 |
A1C represents the percentage of glycosylated hemoglobin.
| Percentage of glycosylated hemoglobin | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1C (A1C) at Week 24 | -1.09 (-1.29 to -0.89) | -0.88 (-1.09 to -0.68) | -1.21 (-1.41 to -1.02) | -1.20 (-1.40 to -1.00) | -1.53 (-1.73 to -1.34) | -1.63 (-1.82 to -1.43) | -1.81 (-2.00 to -1.62) |
| mg/dL | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 | -24.3 (-32.0 to -16.5) | -19.5 (-27.2 to -11.7) | -29.9 (-37.6 to -22.3) | -37.4 (-45.1 to -29.7) | -41.0 (-48.5 to -33.5) | -46.9 (-54.6 to -39.3) | -52.0 (-59.6 to -44.5) |
PMG was measured using the Meal Tolerance Test (MTT).
| mg/dL | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg |
|---|---|---|---|---|---|---|---|
| Change From Baseline in 2-Hour Post-meal Glucose (PMG) at Week 24 | -51.1 (-64.0 to -38.2) | -30.6 (-44.0 to -17.3) | -52.5 (-64.9 to -40.2) | -66.6 (-79.8 to -53.5) | -69.2 (-81.7 to -56.7) | -85.5 (-98.4 to -72.6) | -93.8 (-106.4 to -81.2) |
A1C represents the percentage of glycosylated hemoglobin.
| Percent of glycosylated hemoglobin | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg |
|---|---|---|---|---|---|---|---|
| Change From Baseline in A1C at Week 54 | -0.93 (-1.15 to -0.72) | -0.74 (-0.96 to -0.53) | -1.16 (-1.37 to -0.95) | -1.23 (-1.45 to -1.02) | -1.45 (-1.65 to -1.24) | -1.49 (-1.71 to -1.28) | -1.78 (-1.99 to -1.58) |
| mg/dL | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg |
|---|---|---|---|---|---|---|---|
| Change From Baseline in FPG at Week 54 | -13.1 (-21.6 to -4.5) | -10.5 (-19.0 to -2.0) | -24.0 (-32.4 to -15.5) | -33.3 (-41.8 to -24.8) | -33.9 (-42.2 to -25.7) | -37.1 (-45.5 to -28.6) | -47.8 (-56.1 to -39.5) |
PMG was measured using the Meal Tolerance Test (MTT).
| mg/dL | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg |
|---|---|---|---|---|---|---|---|
| Change From Baseline in 2-Hour PMG at Week 54 | -37.0 (-50.2 to -23.7) | -26.7 (-40.5 to -13.0) | -46.8 (-59.6 to -34.1) | -58.2 (-71.6 to -44.7) | -64.7 (-77.6 to -51.8) | -69.7 (-83.1 to -56.4) | -88.2 (-101.2 to -75.3) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100 mg | — | 14/231 (6.1%) | 60/231 (26%) |
| Pioglitazone 15 mg | — | 10/230 (4.3%) | 41/230 (17.8%) |
| Pioglitazone 30 mg | — | 5/233 (2.1%) | 45/233 (19.3%) |
| Pioglitazone 45 mg | — | 11/230 (4.8%) | 55/230 (23.9%) |
| Sitagliptin 100 mg/ Pioglitazone 15 mg | — | 12/230 (5.2%) | 48/230 (20.9%) |
| Sitagliptin 100 mg/ Pioglitazone 30 mg | — | 15/231 (6.5%) | 56/231 (24.2%) |
| Sitagliptin 100 mg/ Pioglitazone 45 mg | — | 7/230 (3%) | 46/230 (20%) |
| Event | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg |
|---|---|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/231 | 0/230 | 0/233 | 0/230 | 0/230 | 2/231 | 0/230 |
| Coronary artery diseaseCardiac disorders | 2/231 | 0/230 | 0/233 | 0/230 | 1/230 | 0/231 | 0/230 |
| Myocardial infarctionCardiac disorders | 0/231 | 0/230 | 0/233 | 0/230 | 1/230 | 2/231 | 0/230 |
| ArteriosclerosisVascular disorders | 2/231 | 0/230 | 0/233 | 0/230 | 0/230 | 0/231 | 0/230 |
| Atrial flutterCardiac disorders | 0/231 | 0/230 | 0/233 | 0/230 | 0/230 | 0/231 | 1/230 |
| Cardiac failure congestiveCardiac disorders | 0/231 | 0/230 | 0/233 | 0/230 | 0/230 | 0/231 | 1/230 |
| Mitral valve diseaseCardiac disorders | 0/231 | 0/230 | 0/233 | 0/230 | 0/230 | 0/231 | 1/230 |
| Myocardial ischaemiaCardiac disorders | 1/231 | 0/230 | 0/233 | 0/230 | 1/230 | 0/231 | 0/230 |
| Optic ischaemic neuropathyEye disorders | 0/231 | 0/230 | 0/233 | 1/230 | 0/230 | 0/231 | 0/230 |
| Anal fissureGastrointestinal disorders | 0/231 | 0/230 | 0/233 | 0/230 | 0/230 | 0/231 | 1/230 |
| Event | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg |
|---|---|---|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 25/231 | 20/230 | 22/233 | 20/230 | 20/230 | 26/231 | 24/230 |
| HeadacheNervous system disorders | 17/231 | 6/230 | 9/233 | 11/230 | 8/230 | 14/231 | 5/230 |
| NasopharyngitisInfections and infestations | 13/231 | 10/230 | 12/233 | 9/230 | 12/230 | 15/231 | 8/230 |
| HypertensionVascular disorders | 7/231 | 5/230 | 4/233 | 10/230 | 13/230 | 6/231 | 0/230 |
| Upper respiratory tract infectionInfections and infestations | 10/231 | 6/230 | 8/233 | 12/230 | 11/230 | 9/231 | 11/230 |
| Age, Customized(Participants) | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg | Total |
|---|---|---|---|---|---|---|---|---|
| <=20 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 21 to 30 years | 5 | 6 | 2 | 5 | 5 | 8 | 4 | 35 |
| 31 to 40 years | 37 | 39 | 33 | 20 | 17 | 34 | 15 | 195 |
| 41 to 50 years | 64 | 73 | 60 | 70 | 73 | 60 | 68 | 468 |
| 51 to 60 years | 83 | 67 | 88 | 76 | 80 | 75 | 87 | 556 |
| 61 to 70 years | 31 | 34 | 45 | 53 | 44 | 49 | 51 | 307 |
| >70 years | 11 | 11 | 5 | 6 | 11 | 5 | 5 | 54 |
| Sex: Female, Male(Participants) | Sitagliptin 100 mg | Pioglitazone 15 mg | Pioglitazone 30 mg | Pioglitazone 45 mg | Sitagliptin 100 mg/ Pioglitazone 15 mg | Sitagliptin 100 mg/ Pioglitazone 30 mg | Sitagliptin 100 mg/ Pioglitazone 45 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 95 | 82 | 106 | 117 | 112 | 96 | 95 | 703 |
| Male | 136 | 148 | 127 | 113 | 118 | 135 | 135 | 912 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Sep 2008 to primary completion in Oct 2010, 25 months.
Results were first posted in Oct 2011, 11 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Pioglitazone